A recent meta-analysis of predominantly early-stage breast cancer studies showed that PD-L1 positivity (expression on the tumour and/or immune cells) was associated with a worse OS (HR 1.76, 95%CI 1.09–2.82, P = 0.02) and adverse clinicopathological features [11]. The gene discussed is CD274; the disease is breast cancer.